AstraZeneca's Imfinzi increases survival rates in bladder cancer - STAT News
AstraZeneca's Imfinzi, used pre- and post-surgery, improved survival rates in bladder cancer patients, reducing death risk by 25% and recurrence by a third, according to the Phase 3 NIAGARA trial results presented at the European Society for Medical Oncology meeting.
Reference News
NIAGARA Phase III trial results show AstraZeneca's IMFINZI (durvalumab) in combination with chemotherapy significantly improves event-free survival (EFS) and overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients, compared to neoadjuvant chemotherapy alone.
AstraZeneca's Imfinzi, used pre- and post-surgery, improved survival rates in bladder cancer patients, reducing death risk by 25% and recurrence by a third, according to the Phase 3 NIAGARA trial results presented at the European Society for Medical Oncology meeting.
Imfinzi showed no new safety signals in neoadjuvant and adjuvant settings, with 69% of patients experiencing Grade 3 and 4 adverse events. Imfinzi is being tested in various bladder cancer treatments, including the NIAGARA trial, which evaluates its use before and after radical cystectomy. Imfinzi is also approved for multiple cancer treatments, including lung, biliary tract, and endometrial cancers.
The NIAGARA study showed AstraZeneca's Imfinzi improved event-free survival in muscle-invasive bladder cancer, with a 25% reduction in death risk. This contrasts with Bristol Myers Squibb's Opdivo, which was previously approved for adjuvant use. The FDA's cautious stance on perioperative studies may delay Imfinzi's approval, despite its potential impact. Other ongoing trials, like KEYNOTE-866 and VOLGA, aim to further evaluate immunotherapies in this setting.